VC
BBIO icon

VarCov Co’s BridgeBio Pharma BBIO Stock Holding History

VarCov Co’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Buy
+5,020
New +$352K 0.14% 238
2026
Q1 		– Sell
-4,447
Closed -$340K – 390
2025
Q4 		$340K Buy
+4,447
New +$292K 0.13% 258

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

VarCov Co's BBIO Position: Q2 2026 in Review

VarCov Co opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 5,020 shares worth $374K. The stake represents 0.14% of the portfolio and ranks #238 among its holdings. This is a return to the name: VarCov Co previously reported a position in BBIO as recently as Q4 2025.

VarCov Co first reported a position in BBIO in Q4 2025 and has held it in 2 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • VarCov Co held 5,020 shares of BridgeBio Pharma worth $374K as of Q2 2026.
  • BridgeBio Pharma was a new VarCov Co position in Q2 2026.
  • BridgeBio Pharma made up 0.14% of VarCov Co's portfolio in Q2 2026, its #238 holding.
  • VarCov Co first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 2 quarters since.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.